Citrate as an in vivo marker to discriminate prostate cancer from benign prostatic hyperplasia and normal prostate peripheral zone: Detection via localized proton spectroscopy

Kurhanewicz, John; Vigneron, Daniel B.; Nelson, Sarah J.; Hricak, Hedvig; Macdonald, Jeffrey M.; Konety, Badrinath R.; Narayan, Perinchery

doi:10.1016/s0090-4295(99)80016-8

Cited by 199 publications

(133 citation statements)

References 24 publications

Supporting

Mentioning

119

Contrasting

Unclassified

Order By: Relevance

“…Citrate is thus an important in vivo marker of a malignant process. [8][9][10][11] Citrate concentrations in brain tissue (approximately 0.4 mmol/kg 12,13 ) and CSF (approximately 0.2 mmol/L 14 ) are very low, and, to the best of our knowledge, citrate has not been identified with in vivo MR spectroscopy in human brain tissue. …”

Section: Discussionmentioning

confidence: 90%

Citrate in Pediatric CNS Tumors?

Seymour

Panigrahy²,

Finlay³

et al. 2008

AJNR Am J Neuroradiol

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 90%

Citrate in Pediatric CNS Tumors?

Seymour

Panigrahy²,

Finlay³

et al. 2008

AJNR Am J Neuroradiol

View full text Add to dashboard Cite

show abstract

“…Phosphatidylcholine is the most abundant phospholipid in biological membranes, and together with other phospholipids, such as phosphatidylethanolamine and neutral lipids, it forms the characteristic bilayer structure of cells and regulates membrane integrity and function (50,51). High-resolution 31 P and 1 H NMR studies of surgical prostate cancer tissue extracts have demonstrated that many of the compounds involved in phosphatidylcholine and phosphatidylethanolamine synthesis and hydrolysis (choline, phosphocholine, glycerophosphocholine, ethanolamine, phosphoethanolamine, and glycerophosphoethanolamine) contribute to the magnitude of the in vivo "choline" resonance (52)(53)(54)(55)(56). There is also evidence that changes in the cytosolic levels of these phospholipid metabolites correlate with cellular proliferation (57-60) and cellular differentiation (61)(62)(63).…”

Section: Metabolic Identification Of Prostate Cancer-mrsimentioning

confidence: 99%

Combined magnetic resonance imaging and spectroscopic imaging approach to molecular imaging of prostate cancer

Kurhanewicz

Swanson

Nelson

et al. 2002

Magnetic Resonance Imaging

Self Cite

332

266

View full text Add to dashboard Cite

Magnetic resonance spectroscopic imaging (MRSI) provides a noninvasive method of detecting small molecular markers (historically the metabolites choline and citrate) within the cytosol and extracellular spaces of the prostate, and is performed in conjunction with high-resolution anatomic imaging. Recent studies in pre-prostatectomy patients have indicated that the metabolic information provided by MRSI combined with the anatomical information provided by MRI can significantly improve the assessment of cancer location and extent within the prostate, extracapsular spread, and cancer aggressiveness. Additionally, pre-and post-therapy studies have demonstrated the potential of MRI/MRSI to provide a direct measure of the presence and spatial extent of prostate cancer after therapy, a measure of the time course of response, and information concerning the mechanism of therapeutic response. In addition to detecting metabolic biomarkers of disease behavior and therapeutic response, MRI/MRSI guidance can improve tissue selection for ex vivo analysis. High-resolution magic angle spinning ( 1 H HR-MAS) spectroscopy provides a full chemical analysis of MRI/MRSI-targeted tissues prior to pathologic and immunohistochemical analyses of the same tissue. Preliminary 1 H HR-MAS spectroscopy studies have already identified unique spectral patterns for healthy glandular and stromal tissues and prostate cancer, determined the composition of the composite in vivo choline peak, and identified the polyamine spermine as a new metabolic marker of prostate cancer. The addition of imaging sequences that provide other functional information within the same exam (dynamic contrast uptake imaging and diffusion-weighted imaging) have also demonstrated the potential to further increase the accuracy of prostate cancer detection and characterization.

show abstract

“…The polyamine peak resides between the choline and creatine peaks and decreases in the presence of prostate cancer (12,13). Increased turnover of cells in prostate cancer results in a distinctive increase of free choline (11,14), an essential substance in macro-molecules of the cell membrane. While membrane-bound choline cannot be detected by MRSI, free choline within the cytosol or the interstitium can be.…”

Section: Mrsimentioning

confidence: 99%

MRI of the prostate: Clinical relevance and emerging applications

Mazaheri

Shukla–Dave

Muellner

et al. 2011

Magnetic Resonance Imaging

Self Cite

View full text Add to dashboard Cite

MRI of the prostate can aid in many aspects of prostate cancer management, from initial detection to treatment planning and follow-up. This review describes the current strengths and limitations of conventional anatomic and molecular MR imaging techniques (including MR spectroscopic imaging and dynamic contrast-enhanced imaging) for aiding prostate cancer management. It also describes promising emerging approaches for acquiring, analyzing, and applying MR imaging data, and the major research and educational efforts that will be required to realize the potential of prostate MR imaging in routine clinical practice.

show abstract

Citrate as an in vivo marker to discriminate prostate cancer from benign prostatic hyperplasia and normal prostate peripheral zone: Detection via localized proton spectroscopy

Cited by 199 publications

References 24 publications

Citrate in Pediatric CNS Tumors?

Citrate in Pediatric CNS Tumors?

Combined magnetic resonance imaging and spectroscopic imaging approach to molecular imaging of prostate cancer

MRI of the prostate: Clinical relevance and emerging applications

Contact Info

Product

Resources

About